320.56
-3.80 (-1.17%)
Previous Close | 324.36 |
Open | 324.70 |
Volume | 2,094,755 |
Avg. Volume (3M) | 2,078,769 |
Market Cap | 172,246,188,032 |
Price / Earnings (TTM) | 55.27 |
Price / Earnings (Forward) | 15.50 |
Price / Sales | 5.54 |
Price / Book | 28.79 |
52 Weeks Range | |
Earnings Date | 29 Oct 2024 - 4 Nov 2024 |
TTM Dividend Yield | 2.07% |
Profit Margin | 10.12% |
Operating Margin (TTM) | 22.91% |
Diluted EPS (TTM) | 5.81 |
Quarterly Revenue Growth (YOY) | 20.10% |
Quarterly Earnings Growth (YOY) | -45.90% |
Total Debt/Equity (MRQ) | 1,057.30% |
Current Ratio (MRQ) | 1.26 |
Operating Cash Flow (TTM) | 6.45 B |
Levered Free Cash Flow (TTM) | 3.01 B |
Return on Assets (TTM) | 4.48% |
Return on Equity (TTM) | 49.27% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - General (US) | Bullish | Bullish |
Drug Manufacturers - General (Global) | Bullish | Bullish | |
Stock | Amgen Inc. | Bearish | Bullish |
Stockmoo Score
Analyst Consensus | -3.5 |
Insider Activity | NA |
Price Volatility | 2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -0.5 |
Average | -0.50 |
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Investment Style | Large Value |
% Held by Insiders | 0.25% |
% Held by Institutions | 81.67% |
52 Weeks Range | ||
Price Target Range | ||
High | 405.00 (Cantor Fitzgerald, 26.34%) | Buy |
Median | 315.00 (-1.73%) | |
Low | 215.00 (Baird, -32.93%) | Sell |
Average | 320.00 (-0.18%) | |
Total | 2 Buy, 2 Hold, 1 Sell | |
Avg. Price @ Call | 319.43 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Barclays | 07 Oct 2024 | 315.00 (-1.73%) | Hold | 317.45 |
Cantor Fitzgerald | 27 Sep 2024 | 405.00 (26.34%) | Buy | 322.67 |
RBC Capital | 26 Sep 2024 | 362.00 (12.93%) | Buy | 319.10 |
Baird | 25 Sep 2024 | 215.00 (-32.93%) | Sell | 312.86 |
Morgan Stanley | 11 Jul 2024 | 303.00 (-5.48%) | Hold | 325.09 |
No data within this time range.
TTM Dividend Yield | 2.07% |
5Y Average Dividend Yield | 2.85% |
Payout Ratio | 151.03% |
Expected Next Dividend Payment | Mar 2025 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
16 May 2024 | 06 Mar 2024 | 07 Jun 2024 | 2.25 Cash |
15 Feb 2024 | 12 Dec 2023 | 07 Mar 2024 | 2.25 Cash |
16 Nov 2023 | 24 Oct 2023 | 08 Dec 2023 | 2.13 Cash |
17 Aug 2023 | 01 Aug 2023 | 08 Sep 2023 | 2.13 Cash |
17 May 2023 | 07 Mar 2023 | 08 Jun 2023 | 2.13 Cash |
14 Feb 2023 | 12 Dec 2022 | 08 Mar 2023 | 2.13 Cash |
16 Nov 2022 | 28 Oct 2022 | 08 Dec 2022 | 1.94 Cash |
17 Aug 2022 | 03 Aug 2022 | 08 Sep 2022 | 1.94 Cash |
16 May 2022 | 02 Mar 2022 | 08 Jun 2022 | 1.94 Cash |
14 Feb 2022 | 03 Dec 2021 | 08 Mar 2022 | 1.94 Cash |
15 Nov 2021 | 21 Oct 2021 | 08 Dec 2021 | 1.76 Cash |
16 Aug 2021 | 30 Jul 2021 | 08 Sep 2021 | 1.76 Cash |
14 May 2021 | 03 Mar 2021 | 08 Jun 2021 | 1.76 Cash |
11 Feb 2021 | 16 Dec 2020 | 08 Mar 2021 | 1.76 Cash |
13 Nov 2020 | 21 Oct 2020 | 08 Dec 2020 | 1.6 Cash |
14 Aug 2020 | 23 Jul 2020 | 08 Sep 2020 | 1.6 Cash |
15 May 2020 | 04 Mar 2020 | 08 Jun 2020 | 1.6 Cash |
13 Feb 2020 | 11 Dec 2019 | 06 Mar 2020 | 1.6 Cash |
14 Nov 2019 | 22 Oct 2019 | 06 Dec 2019 | 1.45 Cash |
14 Aug 2019 | 02 Aug 2019 | 06 Sep 2019 | 1.45 Cash |
16 May 2019 | 07 Mar 2019 | 07 Jun 2019 | 1.45 Cash |
14 Feb 2019 | 07 Dec 2018 | 08 Mar 2019 | 1.45 Cash |
15 Nov 2018 | 23 Oct 2018 | 07 Dec 2018 | 1.32 Cash |
16 Aug 2018 | 31 Jul 2018 | 07 Sep 2018 | 1.32 Cash |
16 May 2018 | 07 Mar 2018 | 08 Jun 2018 | 1.32 Cash |
14 Feb 2018 | 12 Dec 2017 | 08 Mar 2018 | 1.32 Cash |
16 Nov 2017 | 24 Oct 2017 | 08 Dec 2017 | 1.15 Cash |
15 Aug 2017 | 28 Jul 2017 | 08 Sep 2017 | 1.15 Cash |
15 May 2017 | 07 Mar 2017 | 08 Jun 2017 | 1.15 Cash |
13 Feb 2017 | 20 Dec 2016 | 08 Mar 2017 | 1.15 Cash |
14 Nov 2016 | 14 Oct 2016 | 08 Dec 2016 | 1 Cash |
15 Aug 2016 | 22 Jul 2016 | 08 Sep 2016 | 1 Cash |
13 May 2016 | 02 Mar 2016 | 08 Jun 2016 | 1 Cash |
11 Feb 2016 | 15 Dec 2015 | 08 Mar 2016 | 1 Cash |
12 Nov 2015 | 14 Oct 2015 | 07 Dec 2015 | 0.79 Cash |
13 Aug 2015 | 28 Jul 2015 | 08 Sep 2015 | 0.79 Cash |
12 May 2015 | 04 Mar 2015 | 05 Jun 2015 | 0.79 Cash |
10 Feb 2015 | 17 Dec 2014 | 06 Mar 2015 | 0.79 Cash |
10 Nov 2014 | 17 Oct 2014 | 05 Dec 2014 | 0.61 Cash |
12 Aug 2014 | 25 Jul 2014 | 05 Sep 2014 | 0.61 Cash |
13 May 2014 | 05 Mar 2014 | 06 Jun 2014 | 0.61 Cash |
11 Feb 2014 | 13 Dec 2013 | 07 Mar 2014 | 0.61 Cash |
12 Nov 2013 | 16 Oct 2013 | 06 Dec 2013 | 0.47 Cash |
14 Aug 2013 | 26 Jul 2013 | 06 Sep 2013 | 0.47 Cash |
14 May 2013 | 06 Mar 2013 | 07 Jun 2013 | 0.47 Cash |
11 Feb 2013 | 13 Dec 2012 | 07 Mar 2013 | 0.47 Cash |
Show more |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 4.50 | 2 | 1.40 |
2023 | 8.52 | 4 | 2.96 |
2022 | 7.76 | 4 | 2.96 |
2021 | 7.04 | 4 | 3.13 |
2020 | 6.40 | 4 | 2.78 |
2019 | 5.80 | 4 | 2.41 |
2018 | 5.28 | 4 | 2.71 |
2017 | 4.60 | 4 | 2.65 |
2016 | 4.00 | 4 | 2.74 |
2015 | 3.16 | 4 | 1.95 |
2014 | 2.44 | 4 | 1.53 |
2013 | 1.88 | 4 | 1.65 |
Show more |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |